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Comparison of different risk-adjustment models in
assessing short-term surgical outcome after transthoracic
esophagectomy in patients with esophageal cancer
Dirk J. Bosch, B.Sc.a, Bastiaan B. Pultrum, M.D., Ph.D.a,
ertrude H. de Bock, Ph.D.b, Jurjen K. Oosterhuis, M.D.c,
ichael G. G. Rodgers, M.D.d, John T. M. Plukker, M.D., Ph.D.a,*
aDepartment of Surgery/Surgical Oncology, bDepartment of Epidemiology, cDepartment of Anesthesiology, and dIntensive
are Unit, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30001, 9700 RB
roningen, The NetherlandsAbstract
BACKGROUND: Different risk-prediction models have been developed, but none is generally ac-
cepted in selecting patients for esophagectomy. This study evaluated 5 most frequently used risk-
prediction models, including the American Society of Anesthesiologists, Portsmouth-modified Physi-
ological and Operative Severity Score for the enUmeration of Mortality and morbidity (P-POSSUM),
and the adjusted version for Oesophagogastric surgery (O-POSSUM), Charlson and the Age adjusted
Charlson score to assess postoperative mortality after transthoracic esophagectomy.
METHODS: Data were obtained from 278 consecutive esophageal cancer patients between 1991 and
2007. Performance in predicting postoperative mortality (in-hospital and 90-day mortality) were
analyzed regarding calibration (Hosmer and Lemeshow goodness-of-fit test) and discrimination (area
under the receiver operator curve).
RESULTS: The Hosmer and Lemeshow goodness-of-fit test was applied to each model and showed
a significant outcome for only the P-POSSUM score (P  .035). The receiver operator curve indicated
discriminatory power for P-POSSUM (.766) and for O-POSSUM (.756), other models did not exceed
the minimal surface of .7.
CONCLUSIONS: Postoperative mortality after esophagectomy was best predicted by O-POSSUM.
However, it still overpredicted postoperative mortality.




Comorbidity modelsEsophageal cancer is associated with high rates of periop-
erative morbidity and mortality and a relatively low overall
5-year survival rate of approximately 25%.1 The incidence is
increasing rapidly and appears to be most prominent in vul-
* Corresponding author. Tel.:31-50-361 23 17; fax:31-50-361 48 73.
E-mail address: j.th.plukker@chir.umcg.nl
Manuscript received August 2, 2010; revised manuscript April 19,011
002-9610/$ - see front matter © 2011 Elsevier Inc. All rights reserved.
oi:10.1016/j.amjsurg.2011.04.003nerable and fragile elderly older than age 70 years who with-
stand major surgical insult as well.2 Unfortunately, many el-
derly patients have serious comorbidities interfering with the
outcome of treatment.3,4 Careful preoperative assessment of
fitness and subsequent selection of appropriate surgical candi-
dates are important steps improving short-term outcome for
individuals who undergo an esophagectomy.
New standard treatment methods, including neoadjuvant
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of these patients.5 Nevertheless, surgery remains the pri-
mary curative option.6,7 However, esophagectomy as a
high-risk complex surgical procedure has a severe postop-
erative complication rate of up to 50% with a relatively high
postoperative mortality rate of around 5%, and in some
cohorts approaching 10% to 15%.6,8,9
Preoperative risk stratification for postoperative mortal-
ity may help patients and families address the magnitude of
both the disease and the therapy. It is pivotal for both the
patient and the surgeon to realistically assess the magnitude
of the surgical insult. Therefore, we propose to assess sev-
eral preoperative scoring systems that have each been val-
idated as predictive of severe postoperative morbidity and
mortality.10–14
These risk stratification/adjustment systems include the
Physiological and Operative Severity Score for the enU-
meration of Mortality and morbidity (POSSUM), its Ports-
mouth (P-POSSUM) and O-POSSUM modifications, the
Charlson Comorbidity Index (CCI) with the Age-Adjusted
Charlson Score (ACCI) version and the standard American
Society of Anesthesiologists (ASA) classification systems.
In most of these systems age was not included as a dominant
predictor of morbidity that is uniquely relevant to esopha-
geal cancer presenting nowadays in more aging patients.14
Until now, there were no published studies comparing all 5
of these comorbidity models (P-POSSUM, O-POSSUM,
Charlson, ACCI, and ASA score) for patients after esoph-
agectomy. We examined which of these 5 most frequently
used comorbidity models could predict short-term surgical




Between January 1991 and December 2007 there were
280 consecutive patients with cancer of the esophagus who
underwent a surgical resection with curative intent. Two
patients with missing follow-up data were excluded from
the analysis. In the remaining group of 278 patients an
analysis was performed based on prospectively registered
data from a computerized database of all esophageal proce-
dures at our university hospital (Table 1). Data from this
study were evaluated according to the rules of the ethical
board at our institute. There were no systemic changes over
the study period in the methods of acquiring patient comor-
bidity data.
Preoperative work-up
Preoperative evaluation consisted of physical examina-
tion, standard laboratory tests, and detailed preoperative risk
assessments. Staging was performed by endoscopic ultra- fsonography with fine-needle aspiration of suspected lesions
and 16- to 64-slice multidetector computed tomography of
the chest, abdomen, and cervical region. From 1996 on, all
patients diagnosed as T3-4 or N1 were additionally staged
with 18F-fluoro-2-deoxy-D-glucose positron emission to-
mography (PET) and PET/computed tomography fusion
was applied in case of anatomic difficulties on PET assess-
ment. Since 2007, neoadjuvant chemoradiation consisting
of paclitaxel 50 mg/m2 and carboplatin (area under the
curve [AUC], 2) on days 1, 8, 15, 22, and 29, with concur-
rent radiotherapy of 41.4 Gy (23 fractions of 1.8 Gy), was
administered to 10 patients as part of a randomized control
trial with surgery alone.
Surgery
Surgery in our tertiary referral center was performed by
2 experienced surgeons. All patients underwent a curative
intended open radical transthoracic esophagectomy consist-
ing of a subtotal esophageal resection including a 2-field
lymphadenectomy of nodes at the celiac trunk, along the
upper border of the pancreas, para-aortic region, and medi-
astinal nodes. Pathologic staging was based according to the
latest edition of the TNM classification for esophageal can-
cer.15
Comorbidity and mortality indexes
Overall comorbidity severity was classified according to
the modified P-POSSUM, O-POSSUM, CCI, ACCI, and
ASA scores.
The original POSSUM score overpredicted mortality in
low-risk patients16 and therefore transformed into the Ports-
outh predictor equation (P-POSSUM), with a different
ogistic regression. Both risk prediction models are based on
preoperatively available 12-factor physiological score and
6-factor surgical severity score obtained after surgery. To
Table 1 Variables of P-POSSUM and O-POSSUM






Systolic pressure, mm Hg
Pulse rate, beats/min
Hemoglobin level, g/dL
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was designed17 (Table 1).
The 19 conditions of the CCI were found to influence
survival significantly and were given a weighted, risk-ad-
justed comorbidity index value, varying from 1 to 6 points,
for the individual patient.18 Patients with a low score were
onsidered to have minimal comorbid diseases in their med-
cal history. In our study we used the modification by
omano et al19 because it excludes cancer diagnosis in
etermining comorbidity and is used commonly in cancer
utcomes research. The CCI reflects both the number and
ravity of comorbid diseases. Besides the Charlson score,
e also used the ACCI scoring system, which characterized
he impact of age and comorbidity on disease progression
nd survival after surgery.20 Both models initially were
developed for administrative databases and not for individ-
ual patient level data sets. The commonly used ASA Phys-
ical Status classification is readily available and widely
accepted to stratify surgical patients according to their peri-
operative risk. It varies from ASA 1 (normal healthy patient
in good condition) to ASA 5 (moribund patient, not ex-
pected to survive).21 ASA class is assigned by the attending
anesthesiologist after completing a structured review of
physical status just before the patient’s surgical procedure.
Although the ASA classification was not initially intended
to predict survival beyond the perioperative period, several
investigators have shown a prognostic value for the ASA
classification beyond this period.21
Statistical analysis
The primary outcome was postoperative mortality, which
we defined as death within 90 days after esophagectomy or
any death during admission in the hospital where the resec-
tion was performed. This time period was applied to include
all surgery-related deceased patients. The observed number
of deceased patients was divided by the number of expected
deceased patients and gave a standard mortality ratio
(SMR). The performance of P-POSSUM and O-POSSUM,
CCI, ACCI, and the ASA score in predicting postoperative
mortality was analyzed regarding calibration and discrimi-
nation. Calibration refers to the agreement between ob-
served outcomes and predicted probabilities and concerns
the expected mortality rate for a group of patients. Com-
parison between observed and expected deaths for each
model was analyzed with the Hosmer and Lemeshow (HL)
goodness-of-fit test.22,23 Higher values of the HL statistic
epresent poorer model calibration. In this analysis a P value
f less than .05 was considered to show a statistically
ignificant lack of fit. Discrimination refers to the ability to
istinguish patients who will die from those who will sur-
ive by computing the area under the receiver operating
haracteristic (ROC) curve. Values between .7 and .8 sug-
est reasonable or moderate discrimination and values ex-
eeding .8 suggest good or excellent discrimination.
For a better applicability in clinical practice, both POSSUM
odels were divided into 3 risk categories: group I (lowisk), with a postoperative mortality rate of 0% to less than
%; group II (intermediate risk), with a postoperative mor-
ality rate of 8% to less than 15%; and group III (high risk),
ith a postoperative mortality rate of 15% to 100%.24
To counteract the possibility of changes in hidden care
over the study period (1991–2007), we divided this period
in 3 segments. The predictive powers of these models were
analyzed in each time segment and were compared with the
overall predictive power. All statistical analyses were con-
ducted using the statistical software SPSS 16.0.2 (SPSS,
Inc., Chicago, IL).
Results
The clinicopathologic characteristics of the patients are
summarized in Table 2. The 90-day postoperative mortality
rate was 6.5% (18 patients), including an in-hospital mor-
tality rate of 5.4% (n  15). The overall comorbidity se-
verity evaluated according to the 5 most commonly used
models was as follows.
Evaluation of the POSSUM equation
The expected mortality ratio by P-POSSUM was 6.2% (17
patients), with a SMR of 1.05 (18 of 17). O-POSSUM ex-
pected a postoperative mortality rate of 9.7% (27 patients),
which leads to a SMR of .67 (18 of 27). This value indicates an
overestimation by O-POSSUM. The risk classification of both
POSSUM models, with subdivision in observed and expected
mortality rates, are summarized in Table 3.
Calibration of the HL statistic showed no fit to the
observed data for P-POSSUM (2  16.580; 8 d.f. (degrees
Table 2 Patient (n  278) and tumor characteristics
according to postoperative outcome
Postoperative
survivors




(n  18), (%)
Median age, y
(range)
63 (29y–85y) 70 (55y–81y)
Sex, male/female 214/46 (82.3/17.7) 15/3 (83.3/16.7)
Histology
Adenocarcinoma 218 (83.9) 17 (94.4)
Squamous cell
carcinoma
42 (16.2) 1 (5.6)
Localization
Midesophageal 22 (8.5) 1 (5.5)
Distal esophagus 238 (91.5) 16 (94.5)
Tumor stage
I 38 (14.7) 1 (5.6)
IIa 68 (26.2) 2 (11.1)
IIb 34 (13.1) 0 (.0)
III 107 (41.2) 14 (77.8)
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-POSSUM (2  7.074, 8 d.f.; P  .529; Table 4). The
area under the ROC curve for P-POSSUM was .766 (95%
confidence interval [CI], .67–.86; P  .000), indicating
iscriminatory power for postoperative mortality. A similar
esult was found for O-POSSUM, the ROC curve analysis
evealed discriminatory capability for postoperative deaths
ith an AUC of .756 (95% CI, .67–.84; P  .000).
Evaluation of the CCI and ACCI scores
In our cohort the CCI score ranged from 0 to a maximum of
4 points. Patients with a CCI score of 0 points had an observed
postoperative mortality of 5.6% (8 patients), patients with a
score of 1 point had an observed postoperative mortality of
4.9% (4 patients), patients with a score of 2 points had an
observed postoperative mortality of 11.4% (4 patients), and
patients with a score of 3 points had an observed postoperative
mortality of 12.5% (2 patients); there were no patients with a
score of 4 points (Table 5). The ACCI score in the study group
ranged from 0 to 7 points and showed similar postoperative
mortality rates, with an increased risk of mortality in general
with higher scores (Table 5).
The HL goodness-of-fit test, when applied to the CCI
score, indicated a good fit to the observed postoperative
deaths (2  .833; 2 d.f.; P  .659), as well as the ACCI
Table 3 Outcomes of P-POSSUM and O-POSSUM stratified
for risk groups: observed and expected mortality rates








0 to 8 219 3.7 (8) 3.5 (8)
8 to 15 41 12.2 (5) 10.6 (4)
15–100 18 27.8 (5) 29.1 (5)
Total 278 6.5 (18) 6.2 (17)
O-POSSUM
0 to 8 137 1.5 (2) 4.8 (7)
8 to 15 97 9.3 (9) 11.4 (11)
15–100 44 15.9 (7) 20.8 (9)
Total 278 6.5 (18) 9.7 (27)
*Possum risk group.
Table 4 The 5 risk-adjustment models: calibration and
discrimination
Risk-prediction model HL test (p)
Area under the ROC
curve (95% CI)
P-POSSUM .035 .766 (.67–.86)
O-POSSUM .529 .756 (.67–.84)
CCI score .659 .567 (.42–.71)
ACCI score .270 .684 (.58–.79)
ASA score .210 .635 (.51–.76)core, which showed a similar fit to the observed data (2
5.174; 4 d.f.; P  .270; Table 4). The area under the ROC
curve for the CCI score was .567 (95% CI, .42–.71;
P  .344), indicating no discriminatory power. Similar
esults were found regarding the area under the ROC curve
or the ACCI score, which showed the same poor discrim-
natory power (.684; 95% CI, .58–.79; P  .009). Because
either of the models showed a good fit with the observed
ata, they were not divided into risk categories.
Evaluation of the ASA score
There were no postoperative deaths in the group of
patients with an ASA score of 1. Patients with an ASA score
of 2 had an observed postoperative mortality rate of 6.2%
(11 patients), and in a subsequent ASA score of 3 there were
5 deceased patients (8.3%) were observed. In the highest
ASA score of 4, the observed mortality rate increased to
40.0% (2 patients) (Table 5).
By using the HL goodness-of-fit test, no significant differ-
ence could be found between the observed and expected
frequencies in the ASA classification (2  1.570; 1 d.f.;
P .210; Table 4). The area under the ROC curve (.635; 95%
CI, .51–.76; P .055) did not indicate a discriminatory power.
Therefore, the ASA score was not divided into risk categories.
Specification of mortality incidence during the
time period
To identify possible differences related to changes in
practice over time, the study period (1991–2007) was di-
vided into three 5-year segments. The 90-day mortality rate





0 143 5.6 (8)
1 82 4.9 (4)
2 35 11.4 (4)
3 16 12.5 (2)
4 2 .0 (0)
ACCI
0 20 .0 (0)
1 55 .0 (0)
2 64 7.8 (5)
3 71 7.0 (5)
4 39 12.8 (5)
5 15 .0 (0)
6 12 25.0 (3)
7 2 .0 (0)
ASA
1 36 .0 (0)
2 177 6.2 (11)
3 60 8.3 (5)


































307D.J. Bosch et al. Risk-adjustment models in esophageal cancermortality rate of 6.5%, that is, 5.8% from 1991 to 1996
(P  .854), 8.8% from 1997 to 2002 (P  .396), and 5.7%
rom 2003 to 2007 (P  .721). However, a significant
ortion of the patients who died postoperatively had 1 or
ore severe comorbidities (P  .018). Of cardiovascular
iseases, which occurred frequently, transient ischemic at-
ack/cerebrovascular accident (P  .007) was observed sig-
ificantly more often from 1991 to 1996, hypertension
P  .019) was observed significantly more often between
997 and 2002, and angina pectoris (P  .000) was ob-
erved significantly more often between 2003 and 2007
Table 6). In addition, the predictive power of each model
id not differ in these 3 time periods and both POSSUM
odels had the strongest predictive power in each period.
Comments
Risk stratification in high-risk cancer surgery is pivotal
in identifying patients who may benefit from specific peri-
operative management strategies. Although it is difficult to
define risk factors associated with adverse outcome in indi-
vidual patients, evaluation of postoperative mortality and
morbidity is necessary not only for adequate preoperative
selection of patients but also for a reliable auditing process
comparing outcomes across surgeons and hospitals. In the
present study from a single tertiary-care referral center,
statistical analyses showed the most accurate individual risk
probabilities for O-POSSUM. Overall postoperative mortal-
ity was well predicted by the P-POSSUM equation with a
low rate of underprediction (n 1). Therefore, in our cohort
he P-POSSUM equation is the most powerful predictor
hen comparing different cohorts.
There seems to be a contradiction between the overesti-
ated value of postoperative mortality by O-POSSUM and
ts accurate calibration and discriminatory power for an
ndividual patient. However, predictive accuracy refers to
he ability of a model to assign the correct probability of
eath to patients, whereas discriminatory power refers to the
bility of a model to attribute the correct outcomes to
Table 6 Survival and comorbidity rates in patients during 3 t
Postoperative survivors in periods (%
Overall 1991–1996 1997–200
90-d mortality 260 (93.5) 81 (94.2) 62 (91.2)
Comorbidity, yes/no 114/146 24/57 27/35
Diabetes mellitus 28 (10.8) 5 (6.2) 8 (12.9)
Hypertension 52 (20.0) 7 (8.6) 8 (12.9)
COPD 33 (12.7) 4 (4.9) 8 (12.9)
Angina pectoris 33 (12.7) 11 (13.6) 4 (6.5)
Congestive heart failure 3 (1.2) 0 (.0) 0 (.0)
Myocardial infarction 28 (10.8) 10 (12.3) 4 (6.5)
TIA/CVA 14 (5.4) 1 (1.2) 3 (4.8)
COPD chronic obstructive pulmonary disease; TIA/CVA  transientatients.24 eExternal validation showed varied results regarding prog-
nostic values for these risk-prediction models.11–13,21–27 Two
tudies that compared the P-POSSUM and O-POSSUM
quations showed a poor HL goodness-of-fit for O-POS-
UM, whereas one suggested good predictive power for
-POSSUM.25,26 Several studies evaluated the O-POSSUM
quation and found a variety of results ranging from mod-
rate to good fit.13,24 Only a few studies were performed to
alidate the predictive power of the CCI, ACCI, and ASA
cores after esophagectomy.11,12 In a recent study, an asso-
ciation was suggested between a high Charlson score (2)
and mortality11; 2 other studies indicated a relationship
etween mortality and ASA score.12,21
These varied results may have had several causes. In the
first place, these risk-adjusted models could be interpreted
in various ways by investigators. For example, the ASA
score is defined by an individual anesthetist at a specific
moment and assessments might be influenced by variations
in the clinical presentation. Moreover, the ASA score is
interobserver-dependent and prone to allocation variation.
A second important difference lies in the definition of mor-
tality. Most of the conducted studies used 30-day mortality as
a determinant of surgical outcome, whereas others used in-
hospital mortality. In the present study we used the overall
postoperative mortality, defined as in-hospital and 90-day mor-
tality. Most of the applied risk prediction models are developed
to calculate mortality risk, without any corrections regarding
postadmission death within a reasonable period. In applying
the 90-day mortality, we included all surgery-related deceased
patients. None of these patients died from other circumstances
other than the impact of the surgery. Because many patients
have a predictably short life span we have to rethink the value
of therapeutic strategy if a lot of time would be needed to
recuperate from major surgical stress.
Third, because hospital volume appeared to be an im-
portant prognostic value,6 it would be difficult to identify
redictive risk factors, particularly in a heterogeneous
roup. Therefore, we only examined patients who under-
ent a uniform surgical approach, including a transthoracic
riods
Postoperative deceased patients in periods (%)
003–2007 Overall 1991–1996 1997–2002 2003–2007
19 (94.4) 18 (6.5) 5 (5.8) 6 (8.8) 7 (5.6)
3/56 13/5 2/3 4/2 7/0
15 (12.6) 3 (16.7) 1 (20.0) 2 (33.3) 0 (.0)
37 (31.1) 5 (27.8) 0 (.0) 3 (50.0) 2 (28.6)
21 (17.6) 1 (5.6) 0 (.0) 0 (.0) 1 (14.3)
3 (2.5) 3 (16.7) 0 (.0) 0 (.0) 3 (42.9)
3 (2.5) 0 (.0) 0 (.0) 0 (.0) 0 (.0)
14 (11.8) 3 (16.7) 1 (20.0) 0 (.0) 2 (28.6)
10 (8.4) 2 (11.1) 1 (20.0) 0 (.0) 1 (14.3)
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lthough still premature, recent literature showed a decrease in
everity and frequency of morbidity in patients who underwent
laparoscopic approach, but evidence for a reduced mortality
ate has not been established yet.27,28 None of the patients in
his study had a laparoscopic approach and further research is
ecessary to examine the applicability of these risk-prediction
odels in such a cohort.
A drawback of this study is in its 16-year time span. A
umber of factors affecting survival may have evolved over
his period such as better patient selection or newer tech-
ology, including neoadjuvant chemoradiation and surgical
pproaches. To counteract the possibility of interfering fac-
ors over this period, we divided the time span into 3 almost
qual segments. Mortality rates did not differ significantly
ver this period and statistical analysis indicated the most
redictive power for both POSSUM models in each seg-
ent. The influence of neoadjuvant chemoradiation in this
tudy was low because there was no mortality in this rather
mall group of patients (n  10).
Recently, new risk-adjusted models were developed, in-
luding the Rotterdam, Philadelphia, and Munich scores, to
ompare cohorts, but they do not provide individual risk
tratification, as was clearly concluded by Zingg et al.29
To date, a reliable individual risk-analysis stratification
to guide surgeons and oncologists in the decision making is
missing and it should be performed in the context of an
overall clinical judgment. With a more appropriate risk-
prediction model, we might be able to identify patients with
high estimated morbidity and mortality. A careful selection
based on such models may be helpful to perform adequate
preoperative interventions and reduce the risk of postoper-
ative complications.
Current centralization of this high-risk surgery has led to
a relatively low postoperative morbidity rate, and better
outcomes have been observed in high-volume centers for
moderate- to high-risk patients.30 Predicting the mortality
risk in an individual patient is difficult. The number of
events is too few to justify clinical application of any scor-
ing system without further validation by prospective data in
a clinical trial setting. To counteract the impossibility of the
current models in selecting the individual at-risk patient, we
subdivided the most accurate model into a low-, intermedi-
ate-, and high-risk category. The benefit of this subdivision
for a model is no longer the identification of a rare event, but
to identify a group of patients with an increased mortality
risk. This subdivision may also be valuable to inform pa-
tients participating in clinical studies more accurately and
seems to be useful because it is immediately obvious to
which risk group a patient belongs. To justify this distribu-
tion in clinical practice, more research is necessary to val-
idate this quantification.
Conclusions
Each risk-adjusted model showed a moderate relation-
ship between postoperative mortality and an increased riskscore. We recommend the O-POSSUM for individual risk
stratification because it assessed the condition of the patient
and the risk of surgery most accurately in this study. In
clinical practice we suggest dividing the O-POSSUM score
into a low-, intermediate-, and high-risk category, but before
general application more research is needed to validate our
findings.
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